References
- Lehucher-Ceyrac D, Chaspoux C, Weber MJ et al. Acne, hyperandrogenism and oral isotretinoin resistance – 23 cases. Therapeutic implications. Ann. Dermatol. Venereol. 124, 692–695 (1997).
- Lubbos HG, Hasinski S, Rose LI, Pollock J. Adverse effects of spironolactone therapy in women with acne. Arch. Dermatol. 134, 1162–1163 (1998).
- Shaw JC. Antiandrogen and hormonal treatment of acne. Dermatol Clin. 14, 803–811 (1996).
- Lucky AW, Henderson TA, Olson WH et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J. Am. Acad. Dermatol. 37, 746–754 (1997).
- Pucci E, Petraglia F. Treatment of androgen excess in females: yesterday, today and tomorrow. Gynecol. Endocrinol. 11, 411–433 (1997).
- Young R, Sinclair R. Hirsutes II: treatment. Australas. J. Derm. 39, 151–157 (1998).
- Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J. Am. Acad. Dermatol. 43, 498–502 (2000).
- Redmond GP, Olson WH, Lippman JS et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet. Gynecol. 89, 615–622 (1997).
- Burkman RT. Oral contraceptives: current status. Clin. Obstet. Gynecol. 44, 62–72 (2001).
- Stern RS. Acne therapy. Medication use and sources of care in office-based practice. Arch. Dermatol. 132, 776–780 (1996).
- Bergfeld WF. A lifetime of healthy skin: implications for women. Int. J. Fertil. Wom. Med. 44, 83–95 (1999).
- Gollnick H, Albring M, Brill K. The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type. Ann. Endocrinol. (Paris) 60, 157–166 (1999).
- Gruber DM, Sator MO, Joura EA et al. Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial. Arch. Dermatol. 134, 459–463 (1998).
- Stern RS. Medication and medical service utilization for acne – 1995–1998. J. Am. Acad. Dermatol. 43, 1042–108 (2000).
- Luo S, Martel C, Chen C et al. Daily dosing with flutamide or casodex exerts maximal antiandrogenic activity. Urology 50, 913–919 (1997).
- Vilaplana J, Romaguera C, Azon A, Lecha M. Flutamide photosensitivity – residual vitiliginous lesions. Contact Dermatitis 38, 68–70 (1998).